416 related articles for article (PubMed ID: 10949931)
1. Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells.
Lee TH; Chuang LY; Hung WC
Oncogene; 2000 Aug; 19(33):3766-73. PubMed ID: 10949931
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells.
Lee TH; Chuang LY; Hung WC
Oncogene; 1999 Jul; 18(29):4269-74. PubMed ID: 10435640
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells.
Kim CG; Choi BH; Son SW; Yi SJ; Shin SY; Lee YH
Cell Signal; 2007 Jun; 19(6):1290-300. PubMed ID: 17307334
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen induces the expression of maspin through estrogen receptor-alpha.
Liu Z; Shi HY; Nawaz Z; Zhang M
Cancer Lett; 2004 Jun; 209(1):55-65. PubMed ID: 15145521
[TBL] [Abstract][Full Text] [Related]
5. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Huang L; Sowa Y; Sakai T; Pardee AB
Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357
[TBL] [Abstract][Full Text] [Related]
6. Expression of cyclin D3 through Sp1 sites by histone deacetylase inhibitors is mediated with protein kinase C-delta (PKC-delta) signal pathway.
Kim YH; Lim JH; Lee TJ; Park JW; Kwon TK
J Cell Biochem; 2007 Jul; 101(4):987-95. PubMed ID: 17407153
[TBL] [Abstract][Full Text] [Related]
7. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells.
Xiao H; Hasegawa T; Isobe K
J Cell Biochem; 1999 Jun; 73(3):291-302. PubMed ID: 10321829
[TBL] [Abstract][Full Text] [Related]
8. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
9. As2O3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21WAF1/CIP1 expression in human epidermoid carcinoma A431 cells.
Liu ZM; Huang HS
Cell Signal; 2006 Feb; 18(2):244-55. PubMed ID: 15961274
[TBL] [Abstract][Full Text] [Related]
10. Identification of the promoter of human transcription factor Sp3 and evidence of the role of factors Sp1 and Sp3 in the expression of Sp3 protein.
Lou Z; Maher VM; McCormick JJ
Gene; 2005 May; 351():51-9. PubMed ID: 15857802
[TBL] [Abstract][Full Text] [Related]
11. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells.
Wang Z; Kyo S; Maida Y; Takakura M; Tanaka M; Yatabe N; Kanaya T; Nakamura M; Koike K; Hisamoto K; Ohmichi M; Inoue M
Oncogene; 2002 May; 21(22):3517-24. PubMed ID: 12032853
[TBL] [Abstract][Full Text] [Related]
13. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells.
Mandlekar S; Yu R; Tan TH; Kong AN
Cancer Res; 2000 Nov; 60(21):5995-6000. PubMed ID: 11085519
[TBL] [Abstract][Full Text] [Related]
14. Involvement of PKA and Sp1 in the induction of p27(Kip1) by tamoxifen.
Lee TH; Chang HC; Chuang LY; Hung WC
Biochem Pharmacol; 2003 Aug; 66(3):371-7. PubMed ID: 12907235
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Yokota T; Matsuzaki Y; Miyazawa K; Zindy F; Roussel MF; Sakai T
Oncogene; 2004 Jul; 23(31):5340-9. PubMed ID: 15107822
[TBL] [Abstract][Full Text] [Related]
16. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta stimulation of biglycan gene expression is potentially mediated by sp1 binding factors.
Heegaard AM; Xie Z; Young MF; Nielsen KL
J Cell Biochem; 2004 Oct; 93(3):463-75. PubMed ID: 15372625
[TBL] [Abstract][Full Text] [Related]
18. 17beta-estradiol (E2) induces cdc25A gene expression in breast cancer cells by genomic and non-genomic pathways.
Ru Lee W; Chen CC; Liu S; Safe S
J Cell Biochem; 2006 Sep; 99(1):209-20. PubMed ID: 16598773
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
20. KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1.
Wu J; Lingrel JB
Oncogene; 2004 Oct; 23(49):8088-96. PubMed ID: 15361832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
